keyword
MENU ▼
Read by QxMD icon Read
search

hbv cccDNA

keyword
https://www.readbyqxmd.com/read/28095508/the-smc5-6-complex-restricts-hbv-when-localized-to-nd10-without-inducing-an-innate-immune-response-and-is-counteracted-by-the-hbv-x-protein-shortly-after-infection
#1
Congrong Niu, Christine M Livingston, Li Li, Rudolf K Beran, Stephane Daffis, Dhivya Ramakrishnan, Dara Burdette, Leanne Peiser, Eduardo Salas, Hilario Ramos, Mei Yu, Guofeng Cheng, Michel Strubin, William E Delaney Iv, Simon P Fletcher
The structural maintenance of chromosome 5/6 complex (Smc5/6) is a restriction factor that represses hepatitis B virus (HBV) transcription. HBV counters this restriction by expressing HBV X protein (HBx), which targets Smc5/6 for degradation. However, the mechanism by which Smc5/6 suppresses HBV transcription and how HBx is initially expressed is not known. In this study we characterized viral kinetics and the host response during HBV infection of primary human hepatocytes (PHH) to address these unresolved questions...
2017: PloS One
https://www.readbyqxmd.com/read/28087399/advances-with-using-crispr-cas-mediated-gene-editing-to-treat-infections-with-hepatitis-b-virus-and-hepatitis-c-virus
#2
REVIEW
Buhle Moyo, Kristie Bloom, Tristan Scott, Abdullah Ely, Patrick Arbuthnot
Chronic infections with hepatitis B and hepatitis C viruses (HBV and HCV) account for the majority of cases of cirrhosis and hepatocellular carcinoma. Current therapies for the infections have limitations and improved efficacy is necessary to prevent complications in carriers of the viruses. In the case of HBV persistence, the replication intermediate comprising covalently closed circular DNA (cccDNA) is particularly problematic. Licensed therapies have little effect on cccDNA and HBV replication relapses following treatment withdrawal...
January 10, 2017: Virus Research
https://www.readbyqxmd.com/read/28052637/future-anti-hbv-strategies
#3
REVIEW
Edward J Gane
Although current oral antivirals can maintain viral suppression and reduce the risk of liver-related complications, lifelong therapy is associated with high cost, risk of breakthrough and potential toxicity. There is a need to develop a finite course of treatment which can provide sustained off-treatment virological and clinical response. The likely marker of such a clinical HBV CURE would be HBsAg clearance, but in addition cccDNA elimination would be required to prevent future reactivation (ie complete HBV cure)...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28052622/novel-targets-for-hepatitis-b-virus-therapy
#4
REVIEW
Barbara Testoni, David Durantel, Fabien Zoulim
Treatment with either pegylated interferon-alpha (pegIFN-α) or last generation nucleos(t)ide analogues (NAs) successfully leads to serum viral load suppression in most chronically infected hepatitis B (CHB) patients, but HBsAg loss is only achieved in 10% of the cases after a 5-year follow-up. Thus, therapy must be administered long-term and it will not completely eliminate infection because of the persistent hepatitis B virus (HBV) minichromosome in infected cells, and cannot completely abolish the risk of developing severe sequelae such as cirrhosis and hepatocellular carcinoma...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27998270/pcr-mediated-recombination-impacts-the-analysis-of-hepatitis-b-virus-covalently-closed-circular-dna
#5
Rodolphe Suspène, Valérie Thiers, Jean-Pierre Vartanian, Simon Wain-Hobson
BACKGROUND: The replication of HBV involves the production of covalently closed circular DNA (cccDNA) from the HBV genome through the repair of virion relaxed circular DNA (rcDNA) in the virion. As cccDNA is the transcription template for HBV genomes, it needs to be eliminated from hepatocytes if the eradication of chronic HBV infection is to be achieved. PCR quantitation of cccDNA copy number is the technique of choice for evaluating the efficiency of treatment regimens. The PCR target commonly used to identify cccDNA spans the gapped region of rcDNA and is considered to accurately distinguish between cccDNA and rcDNA...
December 20, 2016: Retrovirology
https://www.readbyqxmd.com/read/27992681/hepatitis-b-virus-core-related-antigen-as-a-surrogate-marker-for-covalently-closed-circular-dna
#6
Danny Ka-Ho Wong, Wai-Kay Seto, Ka-Shing Cheung, Chun-Kong Chong, Fung-Yu Huang, James Fung, Ching-Lung Lai, Man-Fung Yuen
BACKGROUND & AIMS: Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a key to viral persistence in chronic hepatitis B infection. Serum hepatitis B core-related antigen (HBcrAg) is a novel marker for HBV disease. We aimed to determine whether HBcrAg could be a surrogate marker for intrahepatic cccDNA. METHODS: Three hundred and five liver biopsies and the corresponding sera collected from 138 nucleos(t)ide analogues-treated patients were analyzed...
December 19, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27978466/metabolite-identification-of-bentysrepinine-y101-a-novel-anti-hbv-agent-in-rats-using-a-five-step-strategy-based-on-a-combined-workflow-with-two-different-platforms-of-liquid-chromatography-tandem-mass-spectrometry
#7
Huirong Fan, Zhanxing Hu, Ruixing Li, Shiqi Dong, Yuan Gu, Ting Liu, Duanyun Si, Guangyi Liang, Changxiao Liu
Bentysrepinine (Y101), a derivative of repensine (a compound isolated from Dichondrarepens Forst), is a novel phenyalanine dipeptide inhibiting DNA-HBV and cccDNA activities and is currently under development for the treatment of hepatitis B virus (HBV)-infected hepatitis. Our previous study implied that there might be an existence of extensive metabolism of Y101 in rats. Therefore, it is necessary to perform metabolic profiling study to further evaluate its safety and drug-like properties. In this study, the metabolism of Y101 in rats was investigated by a convincible five-step strategy to characterize metabolites in plasma and that excreted into urine, bile and feces...
January 1, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/27975313/immunofluorescent-staining-for-the-detection-of-the-hepatitis-b-core-antigen-in-frozen-liver-sections-of-human-liver-chimeric-mice
#8
Lena Allweiss, Marc Lütgehetmann, Maura Dandri
The hepatitis B virus (HBV) is the causative agent for chronic hepatitis B infection, which affects an estimate of 240 million people worldwide and puts them at risk of developing terminal liver disease. The life cycle of the virus and its interactions with the host immune system are still incompletely understood, and currently available treatment options rarely achieve a cure. Therefore, basic research and new drug development are needed. One parameter for measuring the intrahepatic activity of the virus is monitoring the production of the HBV core antigen (HBcAg), which not only serves as the main structural protein of its nucleocapsid but is also recruited to the covalently closed circular DNA (cccDNA), the nuclear HBV genome responsible for infection persistence...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27975310/a-t7-endonuclease-i-assay-to-detect-talen-mediated-targeted-mutation-of-hbv-cccdna
#9
Kristie Bloom, Abdullah Ely, Patrick Arbuthnot
Gene editing using designer nucleases is now widely used in many fields of molecular biology. The technology is being developed for the treatment of viral infections such as persistant hepatitis B virus (HBV). The replication intermediate of HBV comprising covalently closed circular DNA (cccDNA) is stable and resistant to available licensed antiviral agents. Advancing gene editing as a means of introducing targeted mutations into cccDNA thus potentially offers the means to cure infection by the virus. Essentially, targeted mutations are initiated by intracellular DNA cleavage, then error-prone nonhomologous end joining results in insertions and deletions (indels) at intended sites...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27975309/detection-of-hbv-cccdna-methylation-from-clinical-samples-by-bisulfite-sequencing-and-methylation-specific-pcr
#10
Yongmei Zhang, Richeng Mao, Haitao Guo, Jiming Zhang
Mapping of DNA methylation is essential in understanding the process of HBV covalently closed circular DNA (cccDNA) transcription. Here, bisulfite sequencing PCR and methylation-specific PCR, two PCR-based approaches used in determining and quantifying the DNA methylation pattern, are described.
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27975308/analyses-of-hbv-cccdna-quantification-and-modification
#11
Yuchen Xia, Daniela Stadler, Chunkyu Ko, Ulrike Protzer
Covalently closed circular DNA (cccDNA) serves as the transcriptional template of hepatitis B virus (HBV) replication in the nucleus of infected cells. It ensures the persistence of HBV even if replication is blocked. Immune-mediated killing of infected hepatocytes, cell division, or cytokine induced non-cytolytic degradation of cccDNA can induce the loss of cccDNA. For studies on HBV control, the analysis of cccDNA integrity and its exact quantification is very important. Here, we describe different methods for HBV cccDNA quantification and modification...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27975303/ntcp-reconstituted-in-vitro-hbv-infection-system
#12
Yinyan Sun, Yonghe Qi, Bo Peng, Wenhui Li
Sodium taurocholate cotransporting polypeptide (NTCP) has been identified as a functional receptor for hepatitis B virus (HBV). Expressing human NTCP in human hepatoma HepG2 cells (HepG2-NTCP) renders these cells susceptible for HBV infection. The HepG2-NTCP stably transfected cell line provides a much-needed and easily accessible platform for studying the virus. HepG2-NTCP cells could also be used to identify chemicals targeting key steps of the virus life cycle including HBV covalent closed circular (ccc) DNA, and enable the development of novel antivirals against the infection...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27968847/bushenjianpi-formula-combined-with-entecavir-for-hbeag-negative-chronic-hepatitis-b-patients-a-multicentre-randomised-double-blind-placebo-controlled-trial
#13
Yue-Qiu Gao, Xin Zhang, Man Li, Zhen-Hua Zhou, Xue-Hua Sun, Xiao-Jun Zhu, Shu-Gen Jin
BACKGROUND: The treatment combination of traditional Chinese medicine with western medicine results in significant decrease of serum hepatitis B virus (HBV) DNA and increase of HBeAg loss in patients with HBeAg-positive chronic hepatitis B (CHB) without any serious adverse events. We aimed to assess whether the Bushenjianpi Formula combined with entecavir could increase the HBsAg loss rate in patients with HBeAg-negative CHB. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, we recruited patients with HBeAg-negative CHB from ten third-level grade-A hospital of Traditional Chinese Medicine...
October 2016: Lancet
https://www.readbyqxmd.com/read/27882060/simple-and-reliable-method-to-quantify-the-hepatitis-b-viral-load-and-replicative-capacity-in-liver-tissue-and-blood-leukocytes
#14
Claudia Minosse, Sabrina Coen, Ubaldo Visco Comandini, Raffaella Lionetti, Marzia Montalbano, Stefano Cerilli, Donatella Vincenti, Andrea Baiocchini, Maria R Capobianchi, Stefano Menzo
BACKGROUND: A functional cure of chronic hepatitis B (CHB) is feasible, but a clear view of the intrahepatic viral dynamics in each patient is needed. Intrahepatic covalently closed circular DNA (cccDNA) is the stable form of the viral genome in infected cells, and represents the ideal marker of parenchymal colonization. Its relationships with easily accessible peripheral parameters need to be elucidated in order to avoid invasive procedures in patients. OBJECTIVES: The goal of this study was to design, set up, and validate a reliable and straightforward method for the quantification of the cccDNA and total DNA of the hepatitis B virus (HBV) in a variety of clinical samples...
October 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27864147/host-factor-prpf31-is-involved-in-cccdna-production-in-hbv-replicating-cells
#15
Wataru Kinoshita, Naoki Ogura, Koichi Watashi, Takaji Wakita
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) plays a central role in chronic HBV infection and replication, and is an important factor for HBV surface antigen loss indicating the endpoint of HBV treatment. However, there is a known problem that current anti-HBV drugs, including interferons and nucleos(t)ide analogues, reduce HBV replication but have a little or no effect on reducing cccDNA. Therefore, the development of new therapeutic agents is necessary to eradicate cccDNA. In this study, we identified pre-mRNA processing factor 31 (PRPF31) by siRNA screening as a factor associated with cccDNA...
January 22, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27855500/treatment-of-hepatitis-b-virus-an-update
#16
Haley Ward, Lydia Tang, Bhawna Poonia, Shyam Kottilil
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse...
December 2016: Future Microbiology
https://www.readbyqxmd.com/read/27819342/minicircle-hbv-cccdna-with-a-gaussia-luciferase-reporter-for-investigating-hbv-cccdna-biology-and-developing-cccdna-targeting-drugs
#17
Feng Li, Liang Cheng, Christopher M Murphy, Natalia J Reszka-Blanco, Yaxu Wu, Liqun Chi, Jianming Hu, Lishan Su
Chronic Hepatitis B Virus (HBV) infection is generally not curable with current anti-viral drugs. Virus rebounds after stopping treatment from the stable HBV covalently-closed-circular DNA (cccDNA). The development of drugs that directly target cccDNA is hampered by the lack of robust HBV cccDNA models. We report here a novel HBV cccDNA technology that will meet the need. We engineered a minicircle HBV cccDNA with a Gaussia Luciferase reporter (mcHBV-GLuc cccDNA), which serves as a surrogate to measure cccDNA activity...
November 7, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27797587/the-current-status-and-future-directions-of-hepatitis-b-antiviral-drug-discovery
#18
Liudi Tang, Qiong Zhao, Shuo Wu, Junjun Cheng, Jinhong Chang, Ju-Tao Guo
The current standard care of chronic hepatitis B fails to induce a durable off-drug control of hepatitis B virus (HBV) replication in the majority of treated patients. The primary reasons are its inability to eliminate the covalently closed circular (ccc) DNA, the nuclear form of HBV genome, and restoration of the dysfunctional host antiviral immune response against the virus. Accordingly, discovery and development of therapeutics to completely stop HBV replication, eliminate or functionally inactivate cccDNA as well as activate a functional antiviral immune response against HBV are the primary efforts for finding a cure for chronic hepatitis B...
January 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/27793933/apoptosis-of-hepatitis-b-virus-expressing-liver-tumor-cells-induced-by-a-high-concentration-of-nucleos-t-ide-analogue
#19
Eunyoung Tak, Shin Hwang, Han Chu Lee, Gi-Young Ko, Chul-Soo Ahn, Young-In Yoon, Young-Suk Lim, Dae-Young Jun, Ki-Hun Kim, Gi-Won Song, Deog-Bok Moon, Baek-Yeol Ryoo, Nayoung Kim, Sung-Gyu Lee
BACKGROUND/AIM: We investigated the expression of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and HBV X protein (HBx) in human hepatocellular carcinoma (HCC) and evaluated the effect of high-concentration nucleos(t)ide analogs (NUCs) on liver tumor cell lines. MATERIALS AND METHODS: This study consisted of three parts: part I used human blood and non-tumor liver tissues; part II used human HCC and adjacent liver tissues; and part III used an HBV-expressing liver tumor cell line...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27788717/-potential-clinical-significance-of-hbv-rna-virus-like-particle
#20
F M Lu, J Wang, H Zhuang
Our recent studies confirmed that the HBV RNAs present in the serum of chronic hepatitis B(CHB)patients are pregenomic RNAs(pgRNAs)with a size of 3.5 kb. These pgRNAs are located in virus-like particles whose morphological structure is similar to that of Dan particles. Since pgRNAs can only be transcribed from the covalently closed circular DNA(cccDNA)located in the nuclear of infected hepatocytes, and the production of pgRNAs is not affected by nucleos(t)ide analogues(NUCs), the presence of viral RNA in serum can reflect the presence of cccDNA in hepatocytes and its transcriptional activity in patients treated with medication...
September 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
35092
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"